Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Thyroid Assays Covered by Independence Blue Cross

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Independence Blue Cross has agreed to cover Interpace's thyroid tests, ThyGeNext and ThyraMir, for patients with thyroid cancer.

Independence covers about 2.5 million individuals in Philadelphia and Southeastern Pennsylvania.

According to Interpace, ThyGenX and ThyraMir combination testing for thyroid cancer can help determine whether initial indeterminate thyroid nodules biopsies are malignant or benign compared to standard clinical practice.

"We are pleased that Independence has established a medical policy and criteria for our molecular thyroid tests, and that these Independence members and their physicians now have cost-effective access to our services," Interpace CEO Jack Stover said in a statement.

In April, Interpace received approval to launch its thyroid tests in New York.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.